Psoriasis – Landscape & Forecast – Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) has been challenged by novel, highly effective IL-17 and IL-23 inhibitors. In particular, the uptake of risankizumab (AbbVie’s Skyrizi)—the latest IL-23 inhibitor to be approved for psoriasis—has been phenomenal, raising an alarm for other approved biologics. The expected approvals of bimekizumab, an IL-17 inhibitor; deucravacitinib, an oral tyrosine kinase TYK2 inhibitor; and the nonsteroidal topical agents roflumilast and tapinarof will further increase the number of psoriasis treatments and make the market even more competitive.

Questions answered:

  • How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors (Cosentyx, Taltz, Siliq / Lumicef) and the emerging IL-17 A/F dual inhibitor, bimekizumab, and where are/will these agents be positioned in the psoriasis treatment algorithm?
  • What will be the impact of the IL-23 inhibitors (Tremfya, Ilumya, and Skyrizi), and how will they fare in the competitive psoriasis market?
  • How will the oral TYK2 inhibitor deucravacitinib affect apremilast’s (Amgen’s Otezla’s) patient share, and how will the two agents compare on efficacy and safety attributes?
  • What will be the future of the novel topical therapies roflumilast, a PDE-4 inhibitor, and tapinarof, a TAMA?

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 24 country-specific interviews with thought leaders. Supported by survey data collected for this and other DRG research.

Epidemiology: Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.

Emerging therapies: Phase III/PR: 6 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.

Forecast: 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2029, segmented by brands/generics and epidemiological subpopulations.

Solution Enhancement:

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Psoriasis - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q3 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • November 2020
    • Key Findings
      • Market Outlook
        • Key Findings
          • Market Share of Psoriasis Drug Classes in 2019
          • Market Share of Psoriasis Drug Classes in 2029
          • Psoriasis SWOT Analysis
        • COVID-19: Areas of Potential Forecast Impact
          • Market Drivers and Constraints
            • What Factors Are Constraining the Market for Psoriasis?
            • Major-Market Sales of Select Drug Classes in Psoriasis: 2019-2029
            • Annual Sales of Biologics and Key Oral Agents in Psoriasis: 2019-2029
          • Drug-Class-Specific Trends
            • Patient Share of TNF-Alpha Inhibitors in Moderate to Severe Psoriasis by Country: 2019-2029
            • Brand and Biosimilar Patient Share for TNF-Alpha Inhibitors in Psoriasis: 2019-2029
            • Major-Market Sales of TNF-Alpha Inhibitors and IL-12/23 Inhibitors in Moderate to Severe Psoriasis: 2019-2029
            • Major-Market Patient Share of TNF-Alpha Inhibitors, IL-12/23 Inhibitors, and IL-17 Inhibitors in Moderate to Severe Psoriasis: 2019-2029
            • Major-Market Patient Share of TNF-Alpha Inhibitors, IL-12/23 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors in Moderate to Severe Psoriasis: 2019-2029
            • TYK2 Inhibitors
            • Major-Market Sales of Biologics and Novel Oral Therapies in Moderate to Severe Psoriasis: 2019-2029
            • Major-Market Patient Share of Traditional Oral Drug Classes, PDE-4 Inhibitors, A3 Adenosine Receptor Agonists, and TYK2 Inhibitors in Moderate to Severe Psoriasis: 2019-2029
            • Major-Market Sales of Traditional Oral Drug Classes, PDE4 Inhibitors, A3 Adenosine Receptor Agonists, and TYK2 Inhibitors in Moderate to Severe Psoriasis: 2019-2029
        • Forecast
          • Market Forecast Assumptions
          • Market Forecast Dashboard
        • Etiology and Pathophysiology
          • Etiology
            • Risk Factors
          • Pathophysiology
            • Clinical Features
            • Typical Locations of Psoriasis Lesions
            • Classification of Psoriasis Vulgaris by Phenotype
            • Clinical Forms of Psoriasis
          • Key Pathways and Drug Targets
            • Pathogenesis of Psoriasis and Therapeutic Targets
            • Pathogenesis and Drug Targets
        • Epidemiology
          • Key Findings
            • Epidemiology Populations
              • Disease Definition
              • Methods
              • Sources Used for Diagnosed Symptomatic Prevalence of Psoriasis
              • Number of Diagnosed Symptomatic Prevalent Cases of Psoriasis in the Major Pharmaceutical Markets:u00a02019-2029 (thousands)
              • Disease Definition
              • Methods
              • Sources Used for Diagnosed Symptomatic Prevalent Psoriasis by Severity
              • Sources Used for Drug-Treated Cases of Psoriasis
              • Number of Diagnosed and Drug-Treated Prevalent Cases of Mild Psoriasis in the Major Pharmaceutical Markets: 2019-2029 (thousands)
              • Number of Diagnosed and Drug-Treated Prevalent Cases of Moderate to Severe Psoriasis in the Major Pharmaceutical Markets: 2019-2029 (thousands)
          • Current Treatment
            • Key Findings
              • Treatment Goals
                • Key Endpoints Used in Clinical Trials for Psoriasis
                • Key Physician Insights on Clinical Endpoints
              • Key Current Therapies
                • Overview
                • Mechanism of Action of Key Current Drug Classes Used for Psoriasis
                • Current Therapies Used for Mild Psoriasis
                • Current Therapies Used for Moderate to Severe Psoriasis
                • Market Events Impacting the Use of Key Current Therapies in Psoriasis
                • Advantages and Disadvantages of Etanercept
                • Expert Insight: Etanercept
                • Advantages and Disadvantages of Infliximab
                • Expert Insight: Infliximab
                • Advantages and Disadvantages of Adalimumab
                • Expert Insight: Adalimumab
                • Certolizumab Pegol
                • Advantages and Disadvantages of Certolizumab Pegol
                • Expert Insight: Certolizumab Pegol
                • Advantages and Disadvantages of Ustekinumab
                • Expert Insight: Ustekinumab
                • Advantages and Disadvantages of Secukinumab
                • Expert Insight: Secukinumab
                • Ongoing Clinical Development of Cosentyx
                • Key Ongoing Clinical Trials of Cosentyx in the Treatment of New-Onset Moderate to Severe Psoriasis
                • Advantages and Disadvantages of Ixekizumab
                • Expert Insight: Ixekizumab
                • Advantages and Disadvantages of Brodalumab
                • Expert Insight: Brodalumab
                • Advantages and Disadvantages of Guselkumab
                • Expert Insight: Guselkumab
                • Advantages and Disadvantages of Tildrakizumab
                • Expert Insight: Tildrakizumab
                • Advantages and Disadvantages of Risankizumab
                • Expert Insight: Risankizumab
                • Advantages and Disadvantages of Apremilast
                • Expert Insight: Apremilast
                • Advantages and Disadvantages of Conventional Systemic Therapies
                • Expert Insight: Conventional Systemic Therapies
                • Advantages and Disadvantages of Topical Therapies
                • Expert Insight: Topical Therapies
              • Medical Practice
                • Overview
                • Treatment Guidelines
                • Psoriasis Treatment Guidelines by Market
                • Drug Selection
                • Factors Influencing Drug Selection in Moderate to Severe Psoriasis
                • Preferred Treatment of Psoriasis by Disease Location and Comorbidities
                • Region-Specific Treatment Practices
                • Treatment Decision Tree for Psoriasis: United States
                • Treatment Decision Tree for Psoriasis: France
                • Treatment Decision Tree for Psoriasis: Germany
                • Treatment Decision Tree for Psoriasis: Italy
                • Treatment Decision Tree for Psoriasis: Spain
                • Treatment Decision Tree for Psoriasis: United Kingdom
                • Treatment Decision Tree for Psoriasis: Japan
            • Unmet Need Overview
              • Current and Future Attainment of Unmet Needs in Psoriasis
              • Top Unmet Needs in Psoriasis: Current and Future Attainment
              • Expert Insight: Unmet Needs in Moderate to Severe Psoriasis
            • Emerging Therapies
              • Key Findings
                • Key Emerging Therapies
                  • Therapies in Late-Phase Development for Psoriasis
                  • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Psoriasis
                  • Bimekizumab Profile
                  • Key Ongoing Clinical Trials of Bimekizumab in the Treatment of Psoriasis
                  • Analysis of the Clinical Development Program for Bimekizumab
                  • Expert Insight: Bimekizumab
                  • Expectations for Launch and Sales Opportunity of Bimekizumab in Psoriasis
                  • Piclidenoson Profile
                  • Analysis of the Clinical Development Program for Piclidenoson
                  • Expert Insight: Piclidenoson
                  • Expectations for Launch and Sales Opportunity of Piclidenoson in Psoriasis
                  • Likely Uses of Piclidenoson in the Treatment of Psoriasis
                  • BMS-986165 Profile
                  • Key Ongoing Clinical Trials of BMS-986165 in the Treatment of Psoriasis
                  • Analysis of the Clinical Development Program for BMS-986165
                  • Expert Insight: BMS-986165
                  • Expectations for Launch and Sales Opportunity of BMS-986165 in Psoriasis
                  • Likely Uses of BMS-986165 in the Treatment of Psoriasis
                  • Pefcalcitol Profile
                  • Analysis of the Clinical Development Program for Pefcalcitol
                  • Expectations for Launch and Sales Opportunity of Pefcalcitol in Psoriasis
                  • Tapinarof Profile
                  • Analysis of the Clinical Development Program for Tapinarof
                  • Expectations for Launch and Sales Opportunity of Tapinarof in Psoriasis
                  • Roflumilast Profile
                  • Key Ongoing Clinical Trials of Roflumilast in the Treatment of Psoriasis
                  • Analysis of the Clinical Development Program for Roflumilast
                  • Expert Insight: Roflumilast
                  • Expectations for Launch and Sales Opportunity of Roflumilast in Psoriasis
                • Early-Phase Pipeline Analysis
                  • Select Compounds in Early-Phase Development for Psoriasis
                • Key Discontinuations and Failures in Psoriasis
                • Access & Reimbursement Overview
                  • Region-Specific Reimbursement Practices
                    • Key Market Access Considerations in Psoriasis: United States
                    • General Reimbursement Environment: United States
                    • Key Market Access Considerations in Psoriasis: EU5
                    • General Reimbursement Environment: EU5
                    • Key Market Access Considerations in Psoriasis: Japan
                    • General Reimbursement Environment: Japan
                • Appendix
                  • Key Abbreviations Related to Psoriasis
                  • Brands, Marketers, and Generic Availability of Current Therapies Used for Psoriasis by Market
                  • Psoriasis Bibliography

              launch Related Market Assessment Reports